Pulsenmore Ltd. has announced a $7.5 million private placement with a single healthcare-focused institutional investor to support the next phase of its commercial growth.
The company plans to use the proceeds to expand its U.S. commercial footprint, increase market penetration, fund marketing and commercialization activities, and support working capital and general corporate purposes.
Related: Carvolix secures new €10M tranche, bringing total financing to €20M
Pulsenmore develops home ultrasound technology that enables remote ultrasound examinations outside traditional clinical settings.
CEO Elazar Sonnenschein said:
“This financing supports our next phase of growth and is intended to enable us to further expand our commercial footprint, particularly in the U.S. market, increase market penetration, and execute on strategic initiatives designed to drive long-term growth.”
The financing is expected to close on or around June 26, 2026, subject to customary closing conditions.
